Logo

Aldeyra Therapeutics, Inc.

ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administ… read more

Healthcare

Biotechnology

9 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$5.23

Price

+3.21%

$0.16

Market Cap

$314.206m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$244.530k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$50.619m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.85

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$55.288m

$84.963m

Assets

$29.675m

Liabilities

$15.556m

Debt
Debt to Assets

18.3%

-0.3x

Debt to EBITDA
Free Cash Flow

-$41.037m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases